Saphris
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
OBJECTIVE
To assess clinical features of therapeutic efficacy and tolerability of asenapine (saphris) in stopping acute psychotic…
Asenapine (Saphris®) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the…
To the Editor: Asenapine, marketed as Saphris, is a relatively new psychopharmaceutical agent approved in 2009 for the treatment…
Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of…
Antipsychotic drugs are commonly prescribed for a variety of psychiatric conditions. In addition to individuals with…
The second generation atypical antipsychotic, asenapine (Saphris), was approved by the US FDA (August 2009) for the acute…
On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously…
Antipsychotic agents Asenapine (Saphris—Schering) and iloperidone (Fanapt—Vanda) are new atypical antipsychotic agents that join…
In this article we investigate the post-launch retail prescription trends of asenapine (Saphris(®), Merck and Co.) and…